Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

227
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
227
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

146
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
146
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

185
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
185
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

181
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
181
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

132
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
132
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

170
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PANA-Surv: A Pathway-Guided Adaptive Neighborhood Augmentation Framework Using KEGG Pathways for Multi-Omics Cancer Prognosis.

Genes·2026
Same author

Large scale plasma proteomics: opening up new frontiers of biomarker and therapeutic target discoveries in COPD.

The European respiratory journal·2026
Same author

Bayesian adaptive design for clinical trials with potential subgroup effects.

Statistical methods in medical research·2026
Same author

A Bayesian Multilevel Joint Modeling of Longitudinal and Survival Outcomes in Cluster Randomized Controlled Trial Studies.

Statistics in medicine·2026
Same author

Evaluating the Effectiveness of a Family-Based Lifestyle Intervention for Managing Childhood Overweight: Protocol for a Randomized Controlled Trial.

JMIR research protocols·2025
Same author

scSorterDL: a deep neural network-enhanced ensemble LDAs for single cell classifications.

Briefings in bioinformatics·2025
Same journal

A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials.

Pharmaceutical statistics·2026
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

Adjustment for Inconsistency in Adaptive Phase 2/3 Designs With Dose Optimization.

Cong Chen1, Mo Huang2, Xuekui Zhang3

  • 1Biostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, New Jersey, USA.

Pharmaceutical Statistics
|September 26, 2025
PubMed
Summary
This summary is machine-generated.

Adaptive Phase 2/3 designs in oncology drug development can be improved by addressing dose selection inconsistencies. This study introduces statistical methods to balance regulatory needs, sponsor interests, and practical drug development challenges.

Keywords:
adaptive designdose optimizationinconsistencyphase 2/3 trialseamless designtype I error control

More Related Videos

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.6K

Related Experiment Videos

Last Updated: Jan 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.6K

Area of Science:

  • Clinical Trials Methodology
  • Oncology Drug Development
  • Biostatistics

Background:

  • Adaptive Phase 2/3 designs are crucial for oncology drug development when Phase 1 data is limited.
  • Identifying optimal doses is challenging due to insufficient early-phase data.
  • Inconsistencies between Phase 2 and Phase 3 results pose regulatory and practical hurdles.

Purpose of the Study:

  • To develop statistical methods for adaptive Phase 2/3 designs that explicitly address dose selection inconsistencies.
  • To balance regulatory caution, sponsor interests, and practical considerations in adaptive trial designs.
  • To account for the probability of "picking-the-winner" in dose optimization.

Main Methods:

  • Incorporation of inconsistency concerns into statistical analysis.
  • Specification of an inconsistency cutoff.
  • Utilization of three hypothesis testing strategies: conservative, aggressive, and neutral.
  • Accounting for the probability of "picking-the-winner".

Main Results:

  • The proposed methods provide a framework for managing dose selection imperfections in adaptive Phase 2/3 designs.
  • Demonstrated a way to balance competing interests in adaptive trial design.
  • Highlighted the importance of addressing potential inconsistencies proactively.

Conclusions:

  • The statistical strategies enhance the reliability of adaptive Phase 2/3 designs in oncology.
  • This approach offers a more robust method for dose optimization in drug development.
  • Further research is warranted in this underexplored area of adaptive trial design.